Clostridium difficile Colitis, Treatment and Management
Tóm tắt
Clostridium difficile is a gram positive, anaerobic, spore forming bacilli, which is an ever-present danger within hospitalized patients accounting for ~15,000 deaths each year in the United States CDC (MMWR 61:157–162, 2012). Clostridium difficile infection is generally defined by the presence of diarrhea, leukocytosis and testing positive for the organism’s toxin via toxin assay. As with most bacterial organisms that developed resistance to antibiotics, the organism has developed several fluoroquinolone resistant strains, BI, NAP1, and toxinotype III and ribotype 027 Warney et al. (Lancet 366:1079–1084, 2005). Not only do we see this bacterium with acute and chronic disruption of the intestinal flora, but it has also been associated with chronic proton pump inhibitor usage and elevation of gastric pH Howell et al. (Arch Intern Med 170:784–790, 2010••). Proper hand sanitation and contact precautions are two of the most effective methods in preventing the spread of spores. Treatment modalities for this infection have steadily progressed to include metronidazole, vancomycin, oral administration of IV vancomycin, fidaxomicin, and lastly fecal transplantation. Of greatest importance remains our ability to properly diagnose, treat, and prevent this costly and dangerous infection.
Tài liệu tham khảo
Centers for Disease Control and Prevention. Morbidity and mortality weekly report. Vital signs: preventing Clostridium difficile infection. MMWR Morb Mortal Wkly Rep. 2012;61(09):157–62.
Centers for Disease Control and Prevention. Morbidity and mortality weekly report. 2002; 51: RR-16.
Ciaran K, LaMont TJ. Clostridium difficile—more difficult than ever. N Engl J Med. 2008;359:1932–40.
•• Cohen S et al. Clinical practice guidelines for Clostridium difficile infections in adults: 2010 update by SHEA and IDSA. Infect Control Hosp Epidemiol. 2010; 31(5): 431–55. This is the most recent evidence-based guidelines published by the Infectious Disease Society of America.
http://Drugstore.com. Accessed 11 Dec 2011.
Flatmark A, et al. Early colectomy in severe ulcerative colitis. Scand J Gastroenterol. 1975;10(4):427–31.
Grieco MB, et al. Toxic megacolon complicating crohns colitis. Ann Surg. 1980;191(1):75–80.
• Hempel S et al. Probiotics for prevention and treatment of antibiotic associated diarrhea. JAMA. 2012; 307(18): 1959–69. This article that provides the most recent evidence regarding probiotics and CDI.
•• Howell M et al. Latrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010; 170(9): 784–90. This was the landmark trial that demonstrated an association of proton pump inhibitors and nosocomial CDI.
Jabbar Umair, et al. Effectiveness of alcohol-based hand rubs for removal of Clostridium difficile spores from hand. Infect Control Hospital Epidemiol. 2010;31(6):565–70.
Jarvis WR, et al. National point prevalence of Clostridium difficile in US healthcare facility inpatients, 2009. Am J Infect Control. 2009;37(4):263–70.
Laino C. C. diff on rise in kids—and outside hospital. http://Webmd.com. children’s health section. Accessed 17 June 2012.
Landy J, et al. Faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther. 2011;34(4):409–15.
Linsky A, et al. Proton pump inhibition and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170(9):772–8.
Louie TJ, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422–31.
Mattila E, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012;142:490–6.
Sheth S, LaMont T. Toxic megacolon. http://Uptodate.com. Literature review current through May 2012.
Trudel JL, et al. Toxic megacolon complicating pseudomembranous enterocolitis. Dis Colon Rectum. 1995;38(10):1033.
Wanahita Anna, et al. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med. 2010;115(7):543–6.
Warney M, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366(9491):1079–84.
Wenisch JM, et al. Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2012;56:1974.
Zar FA, et al. A comparison of vancomycin and metronidazole for treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007; 45(3):302–7.